?Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
receiving a positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use for a higher dosage of Wegovy. ?The positive opinion is based on improved weight loss results of around 20.7% at 72 weeks in people without diabetes. Management noted that the STEP UP and STEP UP T2D clinical trial program showed that one in three obese people without diabetes in the trial achieved 25% or more weight loss at 72 weeks using Wegovy. Moreover, these results also complement the already proven benefits of the drug, which include significant reduction in cardiovascular risks and reduction in knee pain from osteoarthritis. ?That said, Novo Nordisk A/S (NYSE:NVO) has also applied for a single-dose device to deliver Wegovy 7.2 mg at the European Medicines Agency. Moreover, the company's Semaglutide 7.2 mg is also under review in the United States, the United Kingdom, and several other countries, with decisions expected in the next few months. ?Wall Street has a
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's oral GLP-1RA maintains weight loss from injectable drugs [Yahoo! Finance]Yahoo! Finance
- This is how exposed European Big Pharma is to the U.S. [MSNBC.com]MSNBC.com
- UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress [Yahoo! Finance]Yahoo! Finance
- Prediction: 1 Healthcare Giant Set to Soar in 2026 [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website